CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease: The RESTORE SVD China Randomized Trial Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Biological Versus Chronological Aging: JACC Focus Seminar In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events Novel Transcatheter Mitral Valve Prosthesis for Patients With Severe Mitral Annular Calcification Self-expandable sirolimus-eluting stents compared to second-generation drug-eluting stents for the treatment of the left main: A propensity score analysis from the SPARTA and the FAILS-2 registries Correlation between frequency-domain optical coherence tomography and fractional flow reserve in angiographically-intermediate coronary lesions P2Y12 Inhibitor Monotherapy with Clopidogrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Clinical Trial2018 Dec 10;11(23):2381-2392.

JOURNAL:JACC Cardiovasc Interv. Article Link

Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease: The RESTORE SVD China Randomized Trial

Tang Y, Qiao S, RESTORE SVD China Investigators. Keywords: drug-coated balloon; drug-eluting stent(s); percentage diameter stenosis; small-vessel disease

ABSTRACT


OBJECTIVES - The aim of this study was to evaluate the angiographic efficacy and clinical outcomes of the Restore paclitaxel-coated balloon in a randomized trial designed to enable its approval with an indication for small-vessel disease (SVD).

 

BACKGROUND - Higher rates of restenosis and stent thrombosis limit the effectiveness of drug-eluting stent (DES) treatment of SVD. Whether a drug-coated balloon (DCB)-only strategy is effective in de novo SVD is not yet established.

 

METHODS - In the noninferiority RESTORE SVD China trial, eligible patients with reference vessel diameter 2.25 and 2.75 mm were randomized to the Restore DCB or the RESOLUTE Integrity DES in a 1 : 1 ratio stratified by diabetes and number of lesions treated. Patients with RVD 2.00 and <2.25 mm were enrolled in a nested very small vessel registry. Angiographic and clinical follow-up were planned at 9 months and 1 year, respectively, in all patients. The study was powered for the primary endpoint of 9-month in-segment percentage diameter stenosis.

 

RESULTS - Between August 2016 and June 2017, a total of 230 subjects at 12 sites were randomized to the DCB group (n = 116) or DES group (n = 114); 32 patients were treated with the DCB in the very small vessel cohort. Nine-month in-segment percentage diameter stenosis was 29.6 ± 2.0% with the DCB versus 24.1 ± 2.0% with the DES; the 1-sided 97.5% upper confidence limit of the difference was 10.9%, achieving noninferiority of the DCB compared with the DES (p for noninferiority < 0.001). The DCB and DES had comparable 1-year rates of target lesion failure (4.4% vs. 2.6%, p = 0.72).

 

CONCLUSIONS - In this multicenter randomized trial, the Restore DCB was noninferior to the RESOLUTE DES for 9-month in-segment percentage diameter stenosis. (Assess the Efficacy and Safety of RESTORE Paclitaxel Eluting Balloon Versus RESOLUTE Zotarolimus Eluting Stent for the Treatment of Small Coronary Vessel Disease; NCT02946307).

 

Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.